Skip to main
QURE
QURE logo

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV has significantly increased its peak revenue estimates for the gene therapy AMT-130 in Huntington's disease (HD) to approximately $3 billion, driven by its favorable safety profile and sustained efficacy. The company's commercial infrastructure is strategically positioned to support a robust launch in 2026, enhancing its prospects for rapid physician adoption and solid engagement with advocacy networks. Furthermore, the absence of approved disease-modifying treatments for HD presents a substantial market opportunity, aligning with the high unmet needs within this patient population.

Bears say

uniQure NV is facing significant challenges due to delays in the regulatory approval process for its AMT-130 gene therapy, leading to a reduction in the probability of success from 65% to 55%. Additionally, the company operates without any revenue-generating products and has consistently reported losses since its inception, highlighting its precarious financial position as a clinical-stage entity. Furthermore, the competitive landscape for gene therapies targeting similar indications presents risks to market penetration and pricing, further complicating uniQure's outlook in the evolving gene therapy market.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Nov 6, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.